Avidity Biosciences Inc. (RNA): Price and Financial Metrics

Avidity Biosciences Inc. (RNA): $25.46

1.30 (+5.38%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add RNA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#342 of 360

in industry

RNA Price/Volume Stats

Current price $25.46 52-week high $27.66
Prev. close $24.16 52-week low $4.82
Day low $24.06 Volume 400,055
Day high $26.02 Avg. volume 1,167,393
50-day MA $21.27 Dividend yield N/A
200-day MA $11.48 Market Cap 2.03B

RNA Stock Price Chart Interactive Chart >


Avidity Biosciences Inc. (RNA) Company Bio


Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.


RNA Latest News Stream


Event/Time News Detail
Loading, please wait...

RNA Latest Social Stream


Loading social stream, please wait...

View Full RNA Social Stream

Latest RNA News From Around the Web

Below are the latest news stories about AVIDITY BIOSCIENCES INC that investors may wish to consider to help them evaluate RNA as an investment opportunity.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on December 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,100 shares of its common stock and 3,550 restricted stock units ("RSUs") to two (2) new non-executive employees under the Avidity Bioscie

Yahoo | December 21, 2023

Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced positive AOC 1044 data in healthy volunteers from the Phase 1/2 EXPLORE44™ clinical trial for the treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44). AOC 1044 delivered unprecedented concentrations of phosphorodiamidate morpholino oligomers (PMO) in skeletal muscle with

Yahoo | December 13, 2023

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.

Yahoo | December 1, 2023

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.

Yahoo | November 30, 2023

Company News for Nov 29, 2023

Companies in The News Are: ESLT,RNA,ZS,SDRL

Yahoo | November 29, 2023

Read More 'RNA' Stories Here

RNA Price Returns

1-mo 7.43%
3-mo 150.59%
6-mo 382.20%
1-year 51.01%
3-year 13.26%
5-year N/A
YTD 181.33%
2023 -59.22%
2022 -6.65%
2021 -6.86%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!